NEW YORK (TheStreet) -- CHANGE IN RATINGSAutomatic Data ADP upgraded at Goldman from Neutral to Buy, Goldman Sachs said. $68 price target. Company has superior cyclical earnings power. Beneficial Mutual Bancorp BNCL upgraded to buy at TheStreet Ratings.Brocade BRCD rated new Neutral at Sterne Agee. Valuation call, as the company is still in the early stages of a growth turnaround. Buffalo Wild Wings BWLD upgraded at Wedbush from Neutral to Outperform, Wedbush said. $100 price target. Menu prices are higher but wing costs have remained stable. Capitol Federal CFFN downgraded at KBW to Market Perform, Keefe, Bruyette & Woods said. $12.50 price target. Company should see muted near-term earnings growth. Central Pacific Financial CPF upgraded to hold at TheStreet Ratings.Dollar Tree DLTR upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. New analyst has a $55 price target. Family Dollar FDO upgraded at Credit Suisse from Neutral to Outperform, Credit Suisse said. $81 price target. New analyst believes that the new management team can improve the company's earnings power. Fidelity National FIS upgraded at Baird from Neutral to Outperform, Robert Baird said. $38 price target. Valuation call, as the stock has pulled back 17% since July. Gardner Denver GDI downgraded at Keybanc from Buy to Hold, Keybanc said. Estimates also cut, given lower demand for drilling pumps. Hewlett-Packard HPQ downgraded at Sterne Agee from Buy to Neutral, Sterne Agee said. Company faces both secular and structural headwinds. Informatica INFA upgraded at Baird to Buy, Robert Baird said. $33 price target. Stock is attractive to buy, following a 23% selloff. Marriott MAR downgraded at Lazard from Buy to Neutral, Lazard said. Estimates also cut, as the company is realizing lower RevPAR growth. Marriot downgraded at UBS to Neutral from Buy, UBS said. $42 price target. Valuation call, remain positive on lodging recovery. MarketAxess MKTX rated new Market Perform at BMO. $33 price target. Stock is already pricing in strong expected growth. MeadWestvaco MWV downgraded at Goldman to Neutral, Goldman Sachs said. Company is leveraged to lower bleached board prices. $30 price target. Owens-Illinois OI upgraded at Goldman to Buy, Goldman Sachs said. $28 price target. New CFO is improving the company's capital allocation strategy. Rockwood ROC rated new Buy at BofA/Merrill. $58 price target. Company can see earnings growth accelerate in 2014. Skyworks SWKS rated new Buy at Lazard. $30 price target. Stock can recover and the company emerges as the clear winner from the iPhone 5. Thermo Fisher TMO upgraded at Wells to Outperform from Market Perform, Wells Fargo said. Company is leveraged to a strong mass spectrometer market. Vanguard Natural VNR rated new Buy at UBS. $33 price target. Growing steadily and paying monthly.Zynga ZNGA downgraded at Baird to Neutral, Robert Baird said. $3 price target. Company cut its guidance again. Zynga downgraded at BofA/Merrill from Neutral to Underperform, Bank of America/Merrill Lynch said. $2.70 price target. Estimates also cut, given the company's new guidance.
STOCK COMMENTS / EPS CHANGESAlexion Pharmaceuticals ALXN numbers raised at Oppenheimer. Shares of ALXN now seen reaching $134, Oppenheimer said. Estimates also raised on headroom in the orphan disease franchise. Outperform rating.Endo ENDP numbers cut at UBS. Shares of ENDP now seen reaching $45, UBS said. Estimates also lowered following investor day. Buy rating. Facebook FB estimates, target reduced at JP Morgan. Shares of FB now seen reaching $28, according to JP Morgan. Estimates also cut, given the company's exposure to ZNGA. Overweight rating. Gap GPS estimates, target increased at Piper. GPS estimates were raised through 2014, Piper Jaffray said. Company is carrying sales momentum into the Fall season. Overweight rating and new $42 price target. Informatica INFA numbers cut at JMP. INFA estimates were reduced through 2013, JMP Securities said. Company cut guidance for a second straight quarter. Outperform rating and new $38 price target. Impax Labs IPXL numbers boosted at BofA/Merrill. Shares of IPXL now seen reaching $25, according to Bank of America/Merrill Lynch said. Estimates also upped, as the company is seeing higher generic sales. Underperform rating. Marriott MAR estimates, target raised at Nomura. Shares of MAR now seen reaching $48, according to Nomura. Estimates also increased, given higher expected RevPAR growth. Buy rating. >To submit a news tip, email: firstname.lastname@example.org.
READERS ALSO LIKE:
Twitter and become a fan on Facebook.
For less than $3 per week, you can get full access to Jim Cramer's intraday market commentary and stock trading strategies - sometimes before he says them on TV! Join now.
- Cramer's Top 5: High-Growth IPOs
- 10 Best 2012 Leftovers For Bargain Car Buyers
- 10 Best Apple Products Ever
- Investment & Company Information
- Goldman Sachs
- Credit Suisse